Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates

A conjugate comprising an antibody that specifically binds to receptor tyrosine kinase orphan receptor 1 (ROR1), the antibody being linked site-specifically to at least one payload moiety and comprising one or more non-natural amino acids and:

• (a) (i) a VH region comprising:
• a CDR-H1 comprising at least one of SEQ ID NOs:
• 4 and 171;
• a CDR-H2 comprising at least one of SEQ ID NOs:
• 338 and 505;
• and a CDR-H3 comprising SEQ ID NO:
• 672;
• and (ii) a VL comprising:
• a CDR-L1 comprising SEQ ID NO:
• 839;
• a CDR-L2 comprising SEQ ID NO:
• 844;
• and a CDR-L3 comprising SEQ ID NO:
• 849;
• (b) (i) a VH region comprising:
• a CDR-H1 comprising at least one of SEQ ID NOs:
• 9 and 176;
• a CDR-H2 comprising at least one of SEQ ID NOs:
• 343 and 510;
• and a CDR-H3 comprising SEQ ID NO:
• 677;
• and (ii) a VI region comprising:
• a CDR-L1 comprising SEQ ID NO:
• 839;
• a CDR-L2 comprising SEQ ID NO:
• 844;
• and a CDR-L3 comprising SEQ ID NO:
• 849;
• or
• (c) (i) a VH region comprising:
• a CDR-H1 comprising at least one of SEQ ID NOs:
• 45 and 212;
• a CDR-H2 comprising at least one of SEQ ID NOs:
• 379 and 546;
• and a CDR-H3 comprising SEQ ID NO:
• 713;
• and (ii) a VI region comprising:
• a CDR-L1 comprising SEQ ID NO:
• 839;
• a CDR-L2 comprising SEQ ID NO:
• 844;
• and a CDR-L3 comprising SEQ ID NO:
• 849.